Breast Cancer

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

OPTIMA trial data at ASCO 2026 shows a 50-gene test helps patients with high-risk breast cancer avoid unnecessary and toxic chemotherapy treatments.

Discover five breakthrough breast cancer studies disrupting oncology as global research teams unveil practice-changing data at ASCO 2026 in Chicago.

An inspiring BRCA2 survivor shares her mastectomy journey, launching the Dear Body Project to help women find healing, self-love and community.

Discover how mastectomy-induced sensation loss impacts body image and intimacy, and learn how breast cancer survivors can advocate for their recovery.

A BRCA2-positive previvor shares her 20-year journey, offering empowering advice and community support for those navigating genetic mutation news.

A retired teacher’s plans for "Act II" are derailed by a breast cancer diagnosis, bringing an onslaught of appointments and a double mastectomy.

CURE editor-in-chief Dr. Joshua Sabari explores how ctDNA liquid biopsies could transform breast cancer care while balancing costs and patient anxiety.

FDA approved Datroway for unresectable or metastatic triple-negative breast cancer not eligible for PD-1 or PD-L1 therapy with PFS, OS and response rates vs chemotherapy.

Study finds breast cancer patients with vitamin D deficiency are three times more likely to report moderate pain and receive more opioids after surgery

Oncology nurse Tammy Zinn, an Extraordinary Healer finalist, expanded support through wish-granting programs, counseling and survivorship care for patients with cancer.

Dr. Erica Mayer of Dana-Farber highlights new data on chemotherapy-free HER2+ treatment, ctDNA monitoring and oral SERDs at ESMO Breast 2026.

A survivor shares why advocating for a mammogram past age 75 led to a crucial second diagnosis and why family history means staying vigilant for life.

New research suggests biologic aging and neighborhood-related stress may affect how aerobic exercise influences cognition after breast cancer treatment.

A moving journey through breast cancer, discovering that vulnerability is courage and a diagnosis doesn't have to define your spirit or faith.

The FDA approved Enhertu for certain patients with HER2-positive early-stage breast cancer before and after surgery based on DESTINY trial data.

My experience with cancer has affected the way I think about the health of my pets. Whereas the old me was more fatalistic, the survivor in me would go an extra mile to save a beloved creature.

ctDNA liquid biopsies detect breast cancer at molecular levels to guide personalized therapy and monitor for recurrence or progression.

Experts urge caution with ctDNA testing in early-stage breast cancer, citing "molecular anxiety" and a lack of clear clinical data on survival outcomes.

Learn about the FDA approval of Veppanu, the first PROTAC for ER+/HER2- metastatic breast cancer with ESR1 mutations.

A cancer survivor reflects on the profound power of physician communication, highlighting how words can either validate hope or deepen patient pain.

A breast cancer survivor shares how faith and community prayer provided unexplainable peace and a new mission to offer hope to others in need.

Following the FDA approval of Veppanu for ESR1-mutant breast cancer, Dr. Komal Jhaveri explains this new therapy that destroys cancer receptors.

Phase 3 VIKTORIA-1 trial shows gedatolisib triplet therapy significantly extends progression-free survival for HR+/HER2- advanced breast cancer.